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INTRODUCTION 
Several skin diseases are characterized by the presence of blisters. 
In some, this may be the only morphologic clue to the diagnosis, 
whereas in other disease, blisters may be one of the several 
manifestations. 
The immunobullous disorders are a group of autoimmune 
diseases in which components of the epidermis and basement membrane 
zone are the focus of attack, resulting in the formation of cutaneous and 
mucosal blisters. The autoimmune bullous diseases result from an 
immune response to molecular components of intercellular adhesion 
molecules in desmosomes or the basement membrane zone (BMZ). The 
diagnosis of autoimmune bullous diseases is based on the evaluation of 
clinical findings, histopathology, direct immunofluorescence (DIF), and 
indirect immunofluorescence (IIF).  The autoimmune blistering diseases 
may be subdivided into intraepidermal (pemphigus) and subepidermal 
(pemphigoid) blistering disorders on the basis of the level at which 
blistering occurs.   
Prior to the early 1950s, most generalized bullous diseases were 
considered to be variants of pemphigus, regardless of the level of skin 
cleavage or differences in clinical appearance or course. Pemphigus and 
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pemphigoid, the two most common autoimmune bullous disorders, were 
first well separated by Lever in the early 1950s1  
 With the development and application of immunofluorescence 
microscopy in the mid 1960s further distinctions were made not only 
between pemphigus and pemphigoid but among other autoimmune 
diseases also. Immunofluorescence testing is of utmost value in 
confirming a diagnosis that is suspected by clinical or histologic 
examination. This is especially true in subepidermal bullous diseases 
that often have overlap in the clinical and histologic findings. 
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REVIEW OF LITERATURE 
  A blister is a fluid filled cavity formed with in or beneath the 
epidermis. The fluid consists of tissue fluid, plasma and variable amount 
of inflammatory cells. Artificial distinction has been made into small 
(vesicles, <0.5cm) and large blisters (bullae,>0.5cm). Blisters in the skin 
can occur at any age and may be caused by common infections, rare 
genetic skin diseases or auto immunobullous diseases.  
Depending on the level of blister in the skin, immunobullous 
diseases can be classified into intraepidermal or subepidermal.  
Intraepidermal bullous disorders include: 
Pemphigus vulgaris 
 Variant: pemphigus vegetans 
Pemphigus foliaceous 
 Variant: pemphigus herpetiformis 
 Variant: pemphigus erythematosus 
Intercellular IgA dermatosis 
Paraneoplastic pemphigus (PNP) 
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Subepidermal bullous disorders include: 
Bullous pemphigoid 
 Variant: pemphigoid nodularis 
 Variant: pemphigoid vegetans 
 Variant: lichen planus pemphigoides    
Mucous membrane pemphigoid 
Pemphigoid gestationis 
Linear IgA disease 
 Variant: chronic bullous disease of childhood 
 Variant: linear IgA disease of adults 
Epidermolysis bullosa acquisita 
Bullous systemic lupus erythematosus 
Dermatitis herpetiformis  
Subepidermal autoimmune blistering disorders arise due to antibodies 
targeting various antigens located in the basement membrane zone 
(BMZ). 
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Structure Of Skin Basement Membrane Zone (BMZ) / 
Dermoepidermal Junction (DEJ) 
Skin basement membrane zone (BMZ) is an ultrastructurally 
defined area situated between the epidermis and the dermis. Skin BMZ 
is 0.5-1.0 mm-thick band-like structure that is positively stained by 
periodic acid-Schiff (PAS) stain.  The major function of skin BMZ is to 
serve as an adherent connection between the epidermis and the dermis. 
The skin BMZ can be divided into four ultrastructurally distinct areas:  
1. Hemidesmosome 
2. Lamina lucida  
3. Lamina densa 
4. Sub-lamina densa. 
 
 
STRUCTURE OF BASEMENT MEMBRANE ZONE 
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Hemidesmosome 
It contains BP Ag1 and 2, α6β4 integrin and plectin. The BPAg1 
(BP 230) is located intracellularly whereas the BPAg2 (BP180; 
collagenXVII) is a transmembranous protein that contains an 
intracellular domain, a transmembranous segment, and an extracellular 
domain that projects into the lamina lucida. The extracellular domain of 
BP180 protein contains a collagenous domain interrupted by 16 small 
non-collagenous domains. The largest of these 16 non-collagenous 
domains, NC16A, is located adjacent to the transmembranous segment. 
In addition, a member of the integrin family, α6β4, and plectin (a 
cytoskeleton-associated attachment protein), are also located in this 
area. Anchoring filaments originate at hemidesmosomes and insert into 
the lamina densa. 
Lamina lucida 
Situated between the hemidesmosome and the lamina densa, the 
lamina lucida is electron-lucent under electron microscope. 
Nevertheless, fine filamentous structures are observed in this area and 
are termed anchoring filaments. Anchoring filaments extend from the 
basal keratinocyte hemidesmosomes to the lamina densa, thus traversing 
the lamina lucida. One of the anchoring filament components is a 
member of the laminin family; laminin-5 (kalinin, epiligrin, nicein, 
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BM600).Other lamina lucida located antigens include entactin/nidogen 
and fibronectin.  The laminin family consists of a group of heterotrimers 
of various combinations of three chains,α, β and γ, and are synthesized 
and secreted by keratinocytes. The lamina lucida appears to be the 
weakest zone of the DEJ. It separates easily with heat and suction, with 
treatment with salt solutions and proteolytic enzymes, and in diseases. 
Lamina densa 
Lamina densa, named according to its electron dense appearance 
under electron microscope, is 35-45 nm-thick. The BMZ components 
that are located in this area include: type IV collagen, perlecan (heparan 
sulphate proteoglycan), and laminin-6.Type IV collagen is considered to 
be the major component in this area.  
Sub-lamina densa 
Below the lamina densa, there are fibrillar structures that connect 
the lamina densa onto the dermal plaque-like structures. These fibrillar 
structures have been named anchoring fibrils. Type VII collagen is the 
major component of the anchoring fibrils. Type VII collagen is a 290-
kDa protein synthesized and secreted by both keratinocytes and 
fibroblasts. Other minor fibers that connect to the area beneath lamina 
densa are: oxytalan, elaunin, and elastic fibers. 
  16
Mucosal BMZ also contain identical components as skin BMZ. 
Different antigens have been discovered in the four zones of the BMZ, 
which are the targets for various diseases. Autoantibodies targeting skin 
and/or mucosal BMZ components, like genetic mutations of BMZ 
components, result in histopathologically defined subepidermal 
blistering diseases. Regardless of which BMZ antigen is targeted by 
autoantibodies, the histopathological findings of all autoimmune 
subepidermal blistering diseases are similar. Although the inflammatory 
cell infiltrate may provide clues in the diagnosis of certain diseases, 
such as eosinophilic infiltrate in the diagnosis of BP, they are not always 
reliable and cannot be used as definitive diagnostic criteria. Therefore, 
more specific techniques are required for accurate diagnosis like direct 
and indirect immunofluorescence. 
IMMUNOFLUORESCENCE 
Immunofluorescence is a laboratory technique for demonstrating 
the presence of antibodies in tissues or body fluids. The use of  
immunofluorescence in both diagnosis and research is well recognised 
in dermatology, dating from the description of granular deposits of IgG 
and C3 along the dermoepidermal junction in the lesions of lupus 
erythematosus in 1963.2  Beutner and Jordon (1964), used an IIF 
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technique to demonstrate what was then considered to be intercellular 
substance of stratified squamous epithelium in the serum of patients of 
pemphigus.3 Later, in 1967 Beutner and Jordon described the 
immunological basis of pemphigoid.  
Historically, Coons et al were the first group to work on the use of 
chemically labeled antibodies as reagents for the detection of antigens in 
mammalian tissue. The same authors in 1942 demonstrated the 
pneumococcal antigen in murine tissue by using this technique.4They 
improved the method using fluorescein as the reagent because of the 
brilliance of its fluorescence and the wavelength of its emitted light 
close to the maximum sensitivity of the human retina. In 1963 a report 
of dermoepidermal fluorescent band in the lesion of lupus 
erythematosus was published.2 
A year later Beutner demonstrated an intercellular substance in 
stratified squamous epithelium using IIF technique. Since then there 
have been many refinements and improvements in the techniques. 
The next decade saw the use of immunoelectron microscope 
(IEM) in understanding vesicobullous lesions of the skin. Subsequently 
during the 1980’s western blotting, immunoprecipitation and cell culture 
were brought into use to study the molecular components of skin which 
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are targeted by the autoimmune phenomenon in various bullous 
disorders. 
IMMUNOFLUORESCENCE TECHNIQUES 
Specimen processing 
DIF is performed on normal-appearing skin immediately adjacent 
to a lesion (perilesional skin). If the patient does not have blisters, the 
specimen may be obtained from skin adjacent to erythematous or 
urticarial plaques because the immune deposits are partially or 
completely degraded in inflamed or blistered skin, and DIF may be 
falsely negative.  For IIF, blood, blister fluid or urine may be used.  
 Skin specimen usually obtained by using a punch biopsy or 
surgical biopsy from the perilesional skin. Then it is immediately snap 
frozen for best preservation of the tissue which is done with liquid 
nitrogen and maintained at -80°C. If delay is inevitable due to want of 
transportation, the specimen is placed in a special transport medium like 
Michel’s medium without loss of antigenic expression.5 
Michel’s medium consists of liquid fixative in the form of 
ammonium sulphate which prevents degradation of tissues with immune 
reactants. Use of transport medium maintains a neutral pH; this is best 
achieved by prior washing the biopsy specimen in normal saline or 
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phosphate buffered saline (PBS) to remove blood and serum proteins. 
The biopsy specimen stays in this medium for up to 8 weeks without the 
loss of specific fluorescence.6 
After the biopsy specimen is received at the laboratory liquid 
fixative if any is washed off in neutral buffer.  It is then snap frozen and 
stored at-70°C to -20°C .The method of freezing varies from place to 
place. (Table 1). This can be done using liquid nitrogen or slow freeze in 
cryostat.  
Sections are obtained of the unfixed frozen specimen by cutting in 
a cryostat equipped with an anti role device to correct the tendency of 
the specimen to curl. Four to six microns thick sections are cut and four 
sections are placed on each slide by bringing it close to the knife surface 
so that the sections thaw and become firmly bound to the glass. The 
slides are then air dried to prevent detachment during staining.  
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Table 1. Methods for freezing skin biopsy specimen 
Method Technique Remarks 
Liquid Nitrogen 
Specimen is wrapped in 
aluminium foil or placed 
in a cryotube and then 
immersed into liquid 
nitrogen 
Cryospray 
Specimen is placed on to 
a cryochuck, covered with 
OCT(optimal cutting 
temperature) compound 
and frozen with cryospray 
These methods may 
induce freezing 
artifact, causing 
distortion of the tissue 
architecture 
Cold Hexane 
Involve the use of n 
hexane which is 
maintained at -60° C in a 
low temperature histo 
bath 
This method greatly 
reduces the degree of 
artifact and allows the 
biopsy to be properly 
oriented. 
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Sections on each slide are incubated with FITC labeled antisera 
against IgG, IgA, IgM, C3, and fibrinogen. Each reagent is usually 
incubated for 30 minutes. The non specifically bound reactants are 
removed by washing the slides in a bath of PBS (pH 7.4). Washing 
should be carried out with all reagents for a minimum of thirty minutes. 
Finally stained preparations are mounted in buffered glycerol and 
examined with a fluorescent microscope.7Provided the sections are 
stored in the dark at 4°C; the IF is retained for 48-72 hours. 
Principles of   Immunofluorescence 8, 9 
Fluorescent techniques involve the emission of light of one 
wavelength/colour from a substance being irradiated with the light of 
different wavelength, the emitted light showing a low energy level. The 
fluorochromes used routinely in dermatopathology are fluorescein 
isothiocynate (FITC) and tetra methyl rhodamine isothiocynate 
(TRITC). FITC has an emission wavelength of 525nm and a maximum 
absorption wavelength of 495 nm. It emits apple-green fluorescence. 
TRITC has an emission wavelength of 580nm and a maximum 
absorption wavelength of 555nm. It emits orange-red colour. 
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Spectrofluorometric characteristics 
Substrate Absorption maximum Emission maximum 
FITC conjugate 495nm (blue) 525nm (apple-green) 
TRITC conjugate 555nm (green) 580nm (orange-red) 
 
To visualize the characteristic emission of the dye, different 
excitation and barrier filters must be used. The excitation or primary 
filter is placed between the light source and the tissue section to screen 
out the wavelengths other than those near the excitation maximum of the 
dye and the barrier filter removes all but the emitted wavelength. 
Fluorochrome conjugated antibody preparations are commercially 
available. These have to be stored in dark containers frozen at -200°C. 
The classical fluorescent microscope has a mercury vapour lamp 
that generates a light beam which is reflected by a concave mirror. This 
is projected through collecting lenses to the excitation filter which emits 
a fluorescent light beam. The beam then passes through a condenser on 
to the specimen with the help of a reflecting mirror. This emitted light 
passes through a barrier filter. The resultant pattern of fluorescence is 
then visualized and magnified by the objective and the ocular lenses. 
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There are three basic types of IF used in dermatology: 
Direct Immunofluorescence (DIF) 
It is a one-step procedure used to detect and localize 
immunoreactants deposited in vivo in the patient's skin or mucosa. The 
immunoreactants include antibodies, complement components and 
fibrinogen. The direct test for the tissue fixed antibody uses a frozen 
section of patient’s skin on which is overlaid fluorescein or rhodamine 
conjugated antibody to immunoglobulins and complements. If the tissue 
contains an antibody e.g., IgG, then fluorescein labeled antihuman IgG 
will bind to it when the frozen tissue section is overlaid with a solution 
containing this reagent. Under fluorescent microscope the fluorescein 
attached to antibody is activated and emits an apple green colour. The 
degree of fluorescence (weak, moderate, strong) can only be 
approximated by the microscopist. Antibody titre cannot be determined 
by direct IF.  
Indirect Immunofluorescence (IIF) 
It is a two-step procedure used to identify circulating auto 
antibodies to cutaneous or mucosal structures in a patient's serum. These 
antibodies are most commonly of IgG or IgA classes. Indirect IF is a 
serological test for antibodies in serum or other fluids. The substrates 
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used in the detection of circulating antibodies in bullous diseases 
include human skin,10monkey esophagus,11 guinea pig lip or esophagus, 
and salt-split human skin.12 The sensitivity and specificity of the 
substrates may vary for the various bullous diseases.13  Frozen tissue 
section or cell suspensions of this normal tissue are placed on 
microscope slides. Sections are overlaid with appropriate dilutions of 
serum or other body fluids so that any antibody against normal tissue 
components will bind to them. The final steps of indirect IF are identical 
to DIF. Fluorescein labeled antihuman immunoglobulin or complement 
is overlaid on the tissue section. Sections are washed and examined 
under fluorescent microscope. Titers of antibodies in fluids can be 
determined by IIF. The titer is the last dilution of serum where antibody 
can be detected. 
SUBSTRATES USED IN IIF 
Antibody type Substrates 
Intercellular Normal skin 
Monkey or guinea pig oesophagus 
Rat bladder 
Anti-BMZ Monkey oesophagus 
Rabbit oesophagus/lip 
Guinea pig oesophagus/lip 
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Antibody type Substrates 
Anti-nuclear Human spleen 
Rat spleen 
Rat liver 
Hep2 cells 
 
Complement indirect IF:  
It is a modification of indirect IF for demonstrating complement 
fixing antibodies in fluids. It may be more sensitive than usual indirect 
IF in certain instances. A single IgM antibody or two IgG antibodies 
bound to antigen can generate many molecules of C3. Complement IIF 
makes use of this amplification principle to increase the sensitivity of 
the assay system. It attempts to demonstrate the antibody in serum or 
other tissue fluids. Normal tissue substrate is overlaid with serum or 
other tissue fluid that has been heated to 56°C for 30 min to destroy 
complement fixing activity. Antibody against tissue binds during this 
step. In the second step, the tissue sections are incubated with a source 
of complement such as fresh human serum.  
The complement fixing IgG or IgM antibody that attached to the 
antigen in the first step can now activate complement in the second step 
to generate numerous molecules of C3. They are all deposited at the site 
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of antigen-antibody binding in the tissue. In the third step, sections are 
incubated with fluorescein labeled antihuman C3 antibodies. They bind 
to C3 molecules generated in the second step. Sections are washed and 
examined under fluorescent microscope. In certain situations, few IgG 
or IgM antibodies bind to tissue antigen that they cannot be detected by 
classic indirect IF. However, since these molecules generate many C3 
complement molecules, complement indirect IF may show fluorescence 
at the site of antigen antibody binding. 
Uses of Immunofluorescence in dermatology for the diagnosis of: 
• Pemphigus  vulgaris and its variants 
• Bullous pemphigoid and its variants 
• Pemphigoid (herpes) gestationis 
• Epidermolysis bullosa acquisita 
• Linear IgA bullous dermatosis (LAD )  
& CBDC 
• Dermatitis herpetiformis 
• Discoid lupus erythematosus 
• Systemic lupus erythematosus 
• Lichen planus  
• Porphyria 
• Vasculitis 
• Amyloidosis 
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Ideal Site for Taking Skin Biopsy for IF in Various Skin Conditions 
Condition Biopsy site(s) 
Pemphigus (all forms)  Perilesional 
Uninvolved (buttock) 
Pemphigoid (all forms) Perilesional 
Uninvolved (buttock) 
Pemphigoid (herpes) gestationis Perilesional 
Epidermolysis bullosa acquisita Perilesional 
Linear IgA bullous dermatosis 
(LAD )& CBDC 
Perilesional 
Uninvolved (buttock) 
Dermatitis herpetiformis Uninvolved (buttock) 
Discoid lupus erythematosus Lesional 
Systemic lupus erythematosus Lesional, Sun exposed uninvolved, 
Non sun exposed uninvolved 
Lichen planus  Lesional 
Porphyria Lesional 
Vasculitis Lesional 
Amyloidosis Lesional 
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Several authors have described the positive effect of saline in 
increasing the sensitivity of IF analysis. Judd and Lever showed that 
skin biopsies stored for 24 hours in 0.15 M phosphate buffered saline 
prior to freezing gave a very high incidence of positive readings in 
direct IF.14 It has been suggested that the increase of IF sensitivity by 
saline incubation is due to improved exposure of epitopes and/or by a 
decrease of background staining.15 
 Indirect Split Skin Immunofluorescence  
This method relies on splitting normal skin through the lamina 
lucida. Split normal skin is used as a substrate in an indirect IF method 
to differentiate between antibodies that bind to antigens in the upper 
lamina lucida or hemidesmosomes and to those that bind to antigens in 
the lamina densa or sublamina densa 
Procedures For Splitting The Skin 
1. Incubation with cold 1M NaCl solution 
2. Treatment with proteolytic enzymes 
3. Induction of suction blister 
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Direct Split Skin Immunofluorescence 
Direct IF is performed on patient’s split skin to localise the site of 
antibody deposition. 
Immunofluorescence In Autoimmune Bullous Diseases 
The autoimmune bullous diseases result from an immune 
response against adhesion molecules of the epidermis and basement 
membrane zone (BMZ).16The pemphigus group of diseases is associated 
with antibodies to desmosomal proteins.17, 18 The antibodies in each type 
of pemphigus are directed against a unique desmosomal protein or a 
specific combination of desmosomal proteins . 
Intraepidermal bullous disorders with their target antigen 
Pemphigus type Target desmosomal protein 
Pemphigus vulgaris Desmoglein 3 and desmoglein 1 
Pemphigus foliaceous Desmoglein 1 
Paraneoplastic pemphigus Desmoglein 3, desmoplakin 1, 
desmoplakin 2, BP 230, 
envoplakin, periplakin 
IgA pemphigus Desmocollin 1 
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There is strong direct experimental evidence that antibodies in 
pemphigus vulgaris (PV) and pemphigus foliaceous (PF) cause 
acantholysis and blister formation 17, 19, 20 by directly interfering with 
desmosomal function.21  
The subepidermal bullous diseases are associated with antibodies 
against one or more components of the BMZ.22, 23    
Subepidermal bullous disorder and their target antigen 
Bullous disease Targeted molecule 
BP BP 180, BP 230 (hemidesmosome 
and lamina lucida) 
HG BP 180, BP 230 (hemidesmosome 
and lamina lucida) 
CP BP 180, laminin V 
(hemidesmosome and lamina 
lucida) 
EBA Type VII collagen (anchoring 
fibrils) 
Bullous SLE Type VII collagen (anchoring 
fibrils) 
LAD (adults and children) LAD antigen (BP 180) 
(hemidesmosome and lamina 
lucida) 
DH Unknown 
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The differential diagnosis of a DIF test depends on 4 features:  
1. The primary site of immune deposition 
2. The class of immunoglobulin or other type of immune deposit 
3. The number of immune deposits and, if multiple, the identity of 
the most intense deposits 
4. Deposition in other sites besides the main site.  
With above parameters accurate diagnosis can be made in the 
majority of cases24 
A. “Intercellular space” deposition  
      The intercellular space (ICS) fluorescence pattern results from 
binding of antibodies to desmosomal proteins around the keratinocyte 
cell surface and is characteristic of the pemphigus group of disorders.           
1. IgG deposition in the ICS only 
This pattern is characteristic of all types of pemphigus except IgA 
pemphigus. DIF is positive in 90% to 100% of patients  
The pattern of fluorescence appears continuous around individual 
keratinocytes on scanning magnification and punctate or granular at 
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higher magnification. The latter pattern reflects binding of antibodies to 
desmosome associated proteins. Complement component C3 may be 
seen in a pattern similar to that of IgG.24The frequency and, usually, the 
intensity of C3 deposition are lower than those of IgG.25 
2. IgG deposition in the ICS and BMZ 
The combination of ICS and BMZ deposition may be seen in two 
settings, PE26 and PNP.27 
3.   IgA deposition in the ICS  
  It is characteristic of IgA pemphigus, also known as 
“subcorneal pustular dermatosis with intercellular IgA deposition” 
and “intraepidermal neutrophilic dermatosis with intercellular IgA 
deposition.” Because antibodies are directed against desmosomal 
proteins, the term pemphigus is appropriate for the condition. 
BMZ deposition  
The detection of immune deposits at the BMZ by DIF is 
characteristic of the subepidermal bullous diseases. There are several 
parameters to evaluate for the accurate interpretation of BMZ 
deposition. These include  
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1. The type of immune deposit (including class of 
immunoglobulin)  
2. The number of immune deposits, namely, whether the 
deposition is of one immunoreactant versus multiple 
immunoreactants 
3. The morphology of the fluorescence at the BMZ e.g.  
continuous, discontinuous, linear, granular, and homogeneous28 
4. Evaluation for fluorescence in any other site besides the BMZ, 
such as dermal blood vessels. 
Diseases with immune deposits at dermoepidermal junction29, 30, 31, 32 
• Lupus erythematosus 
• Dermatomyositis 
• Leucocytoclastic vasculitis 
• Bullous pemphigoid 
• Herpes gestationis 
• Epidermolysis bullosa acquisita 
• Dermatitis herpetiformis 
• Linear IgA bullous dermatosis 
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• Porphyria cutanea tarda 
• Lichen planus 
• Rosacea 
There are clues that are helpful in the differential diagnosis. 
Deposition of C3 with significantly higher intensity than IgG strongly 
favors the pemphigoid group of diseases (BP, mucosal pemphigoid, and 
HG). C3 may be the exclusive immunoreactant at the BMZ in patients 
with HG and occasionally BP. The pattern of deposition in BP and HG 
has been described as linear, wavy, tubular, and granular. The variation 
in pattern may result from variations in the angle at which the 
cryosections are made, the intensity of deposition, and the site of 
biopsy.39 In specimens that contain adnexal structures, a similar 
deposition may be seen along the BMZ of follicular and sweat gland 
epithelium. Differentiation between BP and HG is not possible by 
immunofluorescence or histopathology. There is ample evidence 
confirming that HG is a variant of BP induced by pregnancy.35  
If the intensity of IgG deposition at the BMZ is significantly 
higher than that of C3, EBA and bullous SLE are more likely than 
pemphigoid. The differential expression of intensity between IgG and 
C3 among the above disorders is not understood.40 
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Deposition of IgG and C3 seen in EBA can be differentiated from 
BP by salt split skin technique.41 In BP immunoreactants are deposited 
in epidermal side alone or both epidermal and dermal side whereas in 
EBA they are deposited in dermal side. IgG will localize to the roof of 
the split in the majority of patients, to both roof and floor in 10% but 
occasionally to the floor alone.42,43 C3 will always bind to both roof and 
floor.44 Deposition in BP is within the lamina lucida. This site of 
deposition corresponds to the location of the extracellular domain of 
BP180 antigen that contains the dominant epitopes recognized by the 
pathogenic BP antibodies.45 In contrast, deposition of antibodies in EBA 
is in the sublamina densa area where the target antigen, type VII 
collagen within the anchoring fibrils, is present.46 Exclusive deposition 
on the dermal side may also be seen in antiepiligrin disease, also 
referred to as antiepiligrin CP.47 
Pang BK et al has shown that Floor-pattern salt-split skin cannot 
distinguish bullous pemphigoid from epidermolysis bullosa 
acquisita.48BP can present with a floor pattern fluorescence on salt-split 
skin. But toad skin can be used to differentiate the two. Only BP will 
give positive immunofluorescence with toad skin because it has BP and 
not EBA antigen. 
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2. Multiple deposits at the BMZ 
This pattern of deposition strongly favors EBA and bullous SLE 
over the pemphigoid group of diseases. In EBA, intense IgG deposition 
is almost consistently present.37The intensity of C3 deposition is usually 
less than that of IgG. Deposition of IgA is present in approximately two 
thirds of cases and deposition of IgM in approximately one half of 
cases.37The morphologic pattern of deposition is usually homogeneous, 
thick, and broad.49The BMZ of adnexal epithelia reveals similar 
deposition.  
In bullous SLE, approximately 60% of cases reveal BMZ 
deposition indistinguishable from that of EBA.50In the remaining cases, 
the deposition is granular and mimics that seen in cases with nonbullous 
SLE. Compared with nonbullous SLE, bullous SLE is more frequently 
associated with deposition of IgA.50 In the absence of clinical history, it 
is not possible to distinguish EBA, bullous SLE, and nonbullous SLE 
with certainty. Since most patients with bullous SLE have detectable 
antibodies to type VII collagen that is also the target of EBA 
antibodies,51differentiation between bullous SLE and EBA is based on 
an underlying diagnosis of SLE by clinical and serologic criteria. 
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Revised diagnostic criteria for bullous SLE52 
1. A diagnosis of SLE based on ARA criteria. 
2. Vesicles and bullae arising on, but not limited to, sun exposed 
skin. 
3. Histopathology compatible with DH. 
4. Negative or Positive IIF for circulating BMZ antibodies, using 
separated human skin as substrate. 
5. DIF revealing IgG and/or IgM and often IgA at BMZ.  
3. Deposition of IgA at BMZ 
Linear deposition of IgA at the BMZ is characteristic of LAD53, 54 
The so-called chronic bullous disease of childhood reveals identical 
findings   and represents the childhood form of LAD.55, 56 Deposition of 
C3 is present less frequently and with lower intensity compared with 
IgA. 
C. Deposition at the BMZ and blood vessel walls 
Homogeneous deposition of immunoreactants (usually multiple) 
within superficial dermal blood vessel walls, in addition to BMZ 
deposition, is characteristic of PCT and erythropoietic protoporphyria.57 
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D. Papillary dermal deposition  
Granular deposition of IgA and C3 in the papillary dermis and 
along the BMZ is diagnostic of DH58 
False-negative DIF in occurs in approximately 10% of 
specimens59and may result from  
1. Technical error (e.g., by using wrong or weak antisera) 
2. The presence of clinical or subclinical inflammation and early 
blister formation within the biopsy specimen (this is especially 
true in cases with PNP) 
3. The use of a limited panel of antisera that does not include IgA 
antisera (for cases with IgA pemphigus). 
  39
Imunofluorescence Findings In Various Sub Epidermal Bullous 
Disorders 
Disease Findings 
Bullous pemphigoid Linear BMZ IgG/C3 ~ 80% 
IgA/IgM ~ 20% 
Cicatricial pemphigoid Linear BMZ IgG/C3 ~ 80% 
IgA~ 20% 
Epidermolysis bullosa acquisita Linear BMZ IgG ~ 80% 
IgA ~ 30% 
Linear IgA bullous dermatosis 
(LAD & CBDC) 
Linear BMZ IgA ~ 90% 
IgG/C3 ~ 20% 
Dermatitis herpetiformis Granular deposits in dermal 
papillae IgA ~ 100% 
C3/fibrinogen ~ 40% 
IgM ~ 10% 
Bullous systemic lupus 
erythematosus 
Linear or granular BMZ IgG/C3 
IgM ~ 50% ; IgA 60% 
Bullous lichen planus  Colloid bodies IgM/IgA/C3 
Ragged fibrinogen BMZ band 
 
  40
Colloid bodies can also be seen in bullous pemphigoid. These   
homogeneous, fibrillar bodies are histologically, immunohistologically 
and ultra structurally indistinguishable from the colloid bodies found in 
the lesional skin of lichen planus, lupus erythematosus, dermatomyositis 
and several other dermatoses.  
Bullous Disorders with Negative/Nonspecific IF  
Hailey-Hailey disease  
Bullous impetigo  
Grover’s disease  
Acantholytic PR  
Bullous insect bite  
Bullous drug eruption  
Drug induced lichenoid photodermatitis  
Non-IgA associated vasculitis  
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AIM OF THE STUDY 
 
1. To find out the incidence of  various subepidermal bullous 
disorders 
2. To study the age wise distribution  
3. To study the sex distribution 
4. To study the disease association 
5. To study the immunoreactant pattern of subepidermal blisters on 
direct immunofluorescence 
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MATERIALS AND METHODS 
In the present study, total number of bullous disorder patients 
who attended the dermatology OPD, Government General Hospital, 
Chennai from June 2006 to June 2008 were 107. Of these, 70 patients 
had intraepidermal blistering disease and 37 patients had various 
subepidermal bullous disorders. Out of these 37 patients, twenty five 
cases of subepidermal autoimmune bullous disorders (based on clinical 
findings) were included in this study. 
In all the cases a detailed history was taken. Patients were asked 
about the duration of the disease, the extent of skin involvement and the 
presence of oral and other mucous membrane involvement. History of 
urticarial weals and generalized pruritus was noted. History of drug 
intake prior to the onset of lesions was taken.  Precipitating or 
aggravating factors were noted. History suggestive of gluten sensitive 
enteropathy like abdominal pain, diarrhoea and constipation was asked. 
History of fever, joint pain and photosensitivity was noted. History of 
blistering on trivial trauma was taken. History of lesions suggestive of 
lichen planus was also taken. They were enquired about loss of weight, 
loss of appetite, malena and hemetemesis to rule out internal 
malignancy. Treatment history, personal history and family history of 
similar illness was noted. 
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Each patient was carefully examined .The various clinical 
parameters studied include: 
1. Distribution of vesicles/bullae, number, size, shape, content of 
bulla: hemorrhagic or clear fluid 
2. Presence of bulla on erythematous or non erythematous skin 
3. Oral or other mucous membrane involvement 
4. Erosions and crusting 
5. Hair and nail involvement 
6. Palms and soles involvement 
7. Nikolsky and Asboe Hansen sign 
All the clinical findings were recorded in a standard study 
proforma. All the patients enrolled in the study were investigated as 
outlined in the proforma. This study was approved by the Ethical 
Committee. 
Perilesional skin biopsy was performed under strict aseptic 
precautions, under local anaesthesia using 0.5 ml of 2% lignocaine. A 5 
mm disposable punch (Fig.1) was inserted gently into the skin up to the 
subcutis perpendicular to the skin surface and the biopsy specimen was 
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gently squeezed out and detached from its socket by sharp scissors. The 
biopsy specimen was washed in normal saline before putting into the 
Michel’s transport medium (Fig.1). It was labeled and sent to the 
Department of Dermatology, Kasturba Medical College, Manipal for 
direct immunofluorescence. 
In the laboratory, biopsy specimens were washed in buffer for 30 
minutes and then snap frozen. Four micron thick sections were cut in a 
cryostat (Fig.2), set at -18°C. Sections were washed in PBS (phosphate 
buffer saline) for 10 minutes and fan dried for another 10 minutes. 
Sections were then covered with diluted FITC labeled antisera (Fig.3) 
and then incubated in a moist chamber at 37°C for 30 min. Subsequently 
specimens were washed with three changes of PBS over a period of 30 
minutes. Sections were dried, mounted in buffered glycerol and 
examined with fluorescent microscope (Fig.4). 
All the patients were given appropriate treatment including drugs 
such as systemic steroids, dapsone, doxycycline and nicotinic acid. 
Healed lesions were noted for post inflammatory hyper or 
hypopigmentation or milia formation.       
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OBSERVATIONS AND RESULTS 
    Age & Sex Incidence 
Of the 25 cases, 13 were males and 12 females. The age of the 
patient varied from 16 years to 80 years. 18 patients had bullous 
pemphigoid. Of these 18 BP patients 12 were males and 6 females. 
Males’ age ranged from 16 to 80 years with average age of 47 years. 
Females’ age range varied from 40 to 72 years with average age of 61 
years. One patient had linear IgA disease, one patient had Chronic 
bullous dermatosis of childhood (CBDC), two patients had bullous SLE, 
one patient had pemphigoid vegetans, one patient had bullous lichen 
planus and one patient had lichen planus pemphigoides.  
Disease wise distribution of cases 
Diagnosis Total no of cases 
Bullous pemphigoid 18 
Bullous SLE 2 
Linear IgA disease 1 
CBDC 1 
Bullous LP 1 
LP pemphigoides 1 
Pemphigoid vegetans 1 
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Age wise distribution of bullous pemphigoid patients 
 
Age of 
patient(years) 
Bullous pemphigoid 
Percentage 
(%) 
0-9 0 0 
10-19 2 11.1 
20-29 2 11.1 
30-39 0 0 
40-49 3 16.6 
50-59 1 5.5 
60-69 6 33.3 
70-79 3 16.6 
80-89 1 5.5 
total 18 100 
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Sex Wise Distribution of bullous pemphigoid patients 
 
Age of 
patient(years)
Bullous pemphigoid 
Male                     female 
0-9 0 0 
10-19 2 0 
20-29 2 0 
30-39 0 0 
40-49 2 1 
50-59 1 0 
60-69 3 3 
70-79 1 2 
80-89 1 0 
total 12 6 
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 Age wise distribution 
 
Family History 
 None of the 25 cases gave family history of similar illness in the 
family. 
Clinical Manifestations 
 The main presenting complaints were blisters and erosions over 
the skin. Pruritus was the commonest symptom in all the cases. Out of 
18 BP patients 12 had prodromal symptoms like itching and urticarial 
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weals prior to the onset of blisters. Duration between the prodromal 
symptoms and appearance of blisters varied from 1 month to two years. 
Mucous Membrane Involvement 
Six cases of bullous pemphigoid had oral mucosal erosion apart 
from skin lesions. Both the bullous SLE patients had oral erosions.  
Cutaneous Manifestations 
All cases presented with tense bullae and vesicles, except one 
patient of pemphigoid vegetans who presented with vegetative plaques. 
Hemorrhagic bullae were seen in 2 BP patients. Lesions occurred over 
both normal and erythematous skin in 8 cases and over normal skin 
alone in rest of the 17 cases. The lesions were distributed over chest, 
abdomen, back, upper limb, thighs and legs. One case presented with 
only few lesions localised to hands and abdomen. Typical ‘string of 
pearls’ appearance was seen in linear IgA disease and CBDC. In 18 
patients lesions resolved with post inflammatory hypopigmentation 
where as in others it resolved by post inflammatory hyperpigmentation. 
Nikolsky sign was negative in all the cases. In 7 patients, bulla 
spreading sign was positive. 
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Disease Association 
Out of 18 bullous pemphigoid patients 10 patients had various 
associated diseases. 4 patients had diabetes, 5 patients had hypertension, 
1 patient had carcinoma prostate, 4 patients had cystic lesions of various 
organs (kidney, uterus, lung, and liver), 1 patient had renal calculus, and 
1 patient had interstitial lung disease. 
Investigations 
Tzanck smear was negative in all the cases. Five patients had 
elevated blood sugar. Antinuclear antibody test was positive for SLE 
patients. Ultrasonography abdomen showed cystic lesions of various 
organs in four bullous pemphigoid patients. Cysts were seen in lung, 
liver, uterus and kidney. 
Histopathology 
Skin biopsy was done in all the cases from an early blister. All 
cases showed subepidermal bulla. Bulla cavity contained eosinophils 
and fibrin. In the dermis, inflammatory infiltrate consisted of 
eosinophils, lymphocytes and few neutrophils. Skin biopsy was also 
done for other subepidermal bullous disorders and histopathology was 
characteristic. 
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Immunofluorescence 
Bullous Pemphigoid 
All the 18 patients of bullous pemphigoid patients showed C3 
deposition at BMZ. C3 was deposited linearly in 17 patients (Fig.5); 4 
patients showed strong, 11 patients showed moderately strong and 2 
patients showed weak C3 deposition, whereas in one case it was 
deposited in a weak granular pattern. IgG was present in 11 out of 18 
cases i.e. in 61% of cases along with C3 deposition (Fig.6). It was 
present in a linear fashion in all the cases. Two cases showed IgM 
deposition (one linear and the other granular pattern) along with IgG and 
C3. IgA deposition was present in one case of bullous pemphigoid 
(5.5% of cases) in moderately strong discontinuous pattern. Fibrinogen 
deposit was present in 3 out of 18 BP cases (16.6% of cases). One case 
showed colloid bodies with IgM deposition. 
LINEAR IgA DISEASE AND CBDC   
Linear IgA disease patient showed deposition of IgA at BMZ in 
linear pattern (Fig.7).  In CBDC patient, all the five immunoreactants 
were present at BMZ i.e. IgA, IgG, IgM, C3 and fibrinogen, but 
deposition of IgA was stronger as compared to IgG (Fig.8). C3 was 
present in moderately strong linear fashion.  
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BULLOUS SLE 
One Bullous SLE patient showed moderately strong deposition of 
IgG in linear pattern, moderately strong deposition of C3 in granular 
pattern which was present at the floor in the split skin specimen (Fig.9), 
weak linear deposition of IgM, moderately strong linear deposition of 
IgA (Fig.10) and fibrinogen at BMZ. Second patient of Bullous SLE 
showed deposition of IgG and IgM in moderately strong granular 
pattern (Fig.11), linear weak deposition of C3 and moderately strong 
deposition of IgA at BMZ. In this patient blood vessel wall deposits 
composed of fibrinogen were present. 
Bullous lichen planus 
Bullous lichen planus patient showed deposition of strong cluster 
of colloid bodies stained with IgM, also few colloid bodies were present 
which were stained with IgG, C3 and IgA. There was strong ragged 
fibrinogen band present at BMZ (Fig.12). 
Lichen planus pemphigoides 
Lichen planus pemphigoides patient showed moderately strong 
deposition of IgG (Fig.13) and strong deposition of C3 at BMZ. Few 
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colloid bodies stained with IgM and IgA were also present. Also there 
was weak deposition of fibrinogen at BMZ. 
Pemphigoid vegetans 
Pemphigoid vegetans patient showed weak deposition of C3 
(Fig.14) and IgG along with focal deposition of IgA and fibrinogen at 
BMZ.  
Treatment  
Patients were given appropriate treatment to control the disease. 
Course and prognosis 
All the cases responded very well to the treatment and showed excellent 
remission within a month.  No mortality was recorded. The disease free 
interval was variable. 
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DISCUSSION 
Pemphigus vulgaris has been reported to be the most common 
autoimmune blistering disease in eastern countries, such as Malaysia, 
China and India. Whereas in Western Europe, bullous pemphigoid is the 
most common immunobullous disorder. During the study period bullous 
pemphigoid was the commonest subepidermal autoimmune blistering 
disorder .It constituted 30 out of 107 cases (28%). But overall 
pemphigus vulgaris was the commonest blistering disorder (70 out of 
107 cases). 
The mean age of onset of bullous pemphigoid was 56 years in 
males. The age range varied from 16 years to 80 years. Whereas in 
females age range varied from 40 years to 70 years with a mean age of 
61 years. Although the age range for female patients was narrow, they 
had higher mean average age of presentation of disease. This is 
consistent with other studies by lever W F60 and Amos B et al.61 
The youngest patient was 16 year male in our study. Although 
bullous pemphigoid is a disease of the elderly, it can occur in 
individuals less than 40 years. Several cases have been described in 
children. Few cases has also been reported in infants by Oranje AP and 
Amos B et al.61 
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Out of 30 bullous pemphigoid patients 20 were males and 10 
were females, constituting male to female ratio of 2:1. Incidence of 
bullous pemphigoid is more in males as compared to females and 
similar studies were reported by Jung M et al.62  
Out of 18 BP patients 6 had oral lesions (33%).According to the 
literature oral lesion can occur in 10-30 % of patients. Similar studies 
has been reported by Person JR et al.63 
Bullous pemphigoid can be associated with malignancy. Although 
in many studies there is no increase in incidence of malignancy in 
bullous pemphigoid patients, gastric carcinoma is the most common 
malignancy reported by Ogawa H et al 64 in their series of more than 
1000 BP patients. In our study one patient had prostate carcinoma. This 
rare association of prostate adenocarcinoma with bullous pemphigoid 
has been reported by Oztürkcan S et al.65 
Four out of 18 patients (22%) of bullous pemphigoid showed 
cystic lesion of various organs including liver, kidney, lung and uterus. 
Previously no such association has been described in the literature. 
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DIF 
  C3 deposition was seen in 100% of BP cases, linear deposition in 
17 out of 18 patients and weak granular fashion in 1 patient. IgG 
deposition was seen in 66% of patients.ie 12 out of 18 patients, linear in 
4 cases and discontinuous in 8 patients. Chan YC et al have shown in 
their study linear deposits of IgG and C3 along the dermoepidermal 
junction in twenty-one of 23 (91%) patients.66 Similar results have been 
reported by Chang YT et al in their study of 88 patients.67 Harrist TJ and 
Mihm MC have shown that C3 is present in 100% and IgG in 65% to 
95% of patients. 
Positive deposition of C3 but negative staining for IgG on direct 
immunofluorescence (DIF) studies has been noted in some patients.68 
Following factors contribute to false-negative staining for IgG on DIF in 
some BP patients: 
1. Sub threshold IgG in skin specimens 
2. Limited reactivity of commercial antihuman IgG conjugates to the 
IgG4 subclass  
3. Decreased sensitivity of DIF compared with double antibody 
methods for the detection of IgG.  
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The use of sandwich double antibody immunofluorescence 
methods to test for IgG and/or IgG subclasses may be helpful in 
definitively diagnosing BP in patients with negative IgG and positive C3 
staining on DIF68    
One patient of bullous pemphigoid showed colloid bodies stained 
by IgM. Similar colloid bodies has been described by Y. Horiguchi et al 
in  8 out of 18 patients in their studies.69 These homogeneous, fibrillar 
bodies were histologically, immunohistologically and ultrastructurally 
indistinguishable from the colloid bodies found in lesional skins of 
lichen planus, lupus erythematosus, dermatomyositis and several other 
dermatoses.69 In BP, degenerated keratinocytes adjacent to the blister 
roof, may, after undergoing a filamentous change, drop off into the 
dermis and subsequently form homogeneous, fibrillar bodies in the 
uppermost dermis when re epithelization is completed. Some findings 
that may help favor lichen planus include the tendency for cytoid bodies 
in LP to cluster in groups, to be present in high number, to be larger, to 
have higher fluorescent intensity, and to contain multiple immune 
deposits.70 
Two cases of BP also showed weak deposition of IgM along with 
IgG and C3.Fibrinogen deposition was seen in 3 patients of BP apart 
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from other immunoglobulin and C3. Similar results have been shown by 
Ahmed AR et al, 71 and Cormane RH.72 They have shown the deposition 
of IgM, IgA, IgD and IgE at the dermoepidermal junction. This is also 
consistent with the findings of Provost TT and Tomasi TB who have 
shown that IgE, alternate pathway components and fibrinogen can be 
deposited along DEJ in bullous pemphigoid patients.73 
Linear IgA disease patient showed deposition of only IgA at BMZ 
in linear pattern. This is consistent with the diagnosis. Studies by 
Wojnarowska F, Bhogal B and Black MM have shown deposition of 
other immunoreactants also (IgM, IgG and C3) in 20-30% of 
patients.74,75  
 In CBDC patient all the five components were present i.e. IgA, 
IgG, IgM, C3 and fibrinogen, but deposition of IgA was stronger as 
compared to IgG. C3 was present in moderately strong linear fashion 
which is consistent with the diagnosis of CBDC. According to Petersen 
MJ et al that if both IgA and IgG are present and deposition of IgA is 
more intense than IgG, and C3 deposition is strong, than it should be 
considered as a case of linear IgA dermatosis.76   There have been many 
case reports in which there is deposition of only IgG and IgA. These 
cases should be considered as subset of linear IgA disease. Metz BJ et 
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al77 has described a patient of Linear IgA dermatosis with IgA and IgG 
deposition only at BMZ. Similar deposition has been described by 
Watanabe M et al78 and Kersting E et al.79 
Bullous SLE patient showed moderately strong deposition of IgG 
in linear pattern, moderately strong deposition of C3 in granular pattern 
which was present at the floor in the split skin specimen, deposition of 
IgM in weak linear, and IgA and fibrinogen were present in moderately 
strong linear pattern. Another patient of Bullous SLE showed deposition 
of IgG and IgM in moderately strong granular pattern, weak deposition 
of C3 and moderately strong deposition of IgA. 
Similar results have been reported by Gammon WR et al in their 
studies.80They have shown that IgG is always present and IgA and IgM 
are also frequently deposited at the BMZ. The pattern of deposition may 
be granular (60%), linear (40%) or rarely fibrillar.80 A linear rather than 
granular pattern along the BMZ is associated with the presence of higher 
titer of circulating autoantibodies.80 
 Both of the Bullous SLE patients showed deposition of IgA. 
Gammon WR et al have shown that Bullous SLE is associated with a 
higher incidence of IgA deposition (76%) than other forms of SLE 
(17%) and this may also correlate with renal involvement.81 
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Lichen planus pemphigoides patient showed moderately strong 
deposition of IgG and strong deposition of C3 at BMZ. Few colloid 
bodies stained with IgM and IgA were also present in the superficial 
dermis. There was also weak deposition of fibrinogen at BMZ. 
Lichen planus pemphigoides is a rare clinical variant of bullous 
pemphigoid and DIF findings are similar to BP. Okochi H et al have 
drawn conclusion from their study that the presence of C3 alone or with 
IgG along the dermoepidermal junction is confirmatory on DIF
82 Vibhu 
Mendiratta et al have shown deposition of IgG and C3 at BMZ in lichen 
planus pemphigoides patient.83 
Bullous LP patients showed strong cluster of IgM colloid bodies 
in superficial dermis. There were also colloid bodies with weak 
deposition of IgG, C3 and IgA. Also there was strong deposition of 
ragged fibrinogen band along DEJ. A Sandra et al have shown in their 
study of 18 bullous lichen planus patients similar findings.84 In their 
study ragged fibrinogen band was present in all the patients whereas 
colloid bodies demonstrating IgG, C3, IgM and IgA were seen in 88% 
of patients. In bullous lichen planus patients immune deposits are 
present within cytoid bodies in the superficial dermis, as well as along 
the DEJ.85 The most frequently present immune deposits are IgM and 
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fibrinogen.85, 86 Deposition of IgG, IgA, and C3 is less frequently 
present.87, 88  
Gawkrodger DJ et al compared two patients with lichen planus 
pemphigoides and two with bullous lichen planus and showed direct 
immunofluorescence was positive in lichen planus pemphigoides and 
negative in bullous lichen planus.89 
Pemphigoid vegetans patient showed C3 and IgG deposition with 
weak deposition of IgA and fibrinogen. Chan LS et al described a 
patient of pemphigoid vegetans with deposition IgG at BMZ.90 They 
considered it to be a variant of bullous pemphigoid. Marie Ogasawara et 
al described a patient of pemphigoid vegetans with IgA, IgG and weak 
C3 BMZ deposition.91    Lawrence S Chan et al reported a patient of 
pemphigoid vegetans with linear IgG deposition at BMZ.92     IgG, IgM, 
C3 and fibrin deposition has also been described by Winkelmann RK 
and Su WPD who first described this clinical entity.93   Y. Ueda et al 
considered it to be a variant of bullous pemphigoid.94  
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CONCLUSION 
1. Bullous pemphigoid was the most common subepidermal blistering 
disease. 
2. Bullous pemphigoid was twice as common in males as in females. 
3. Rare association of cystic disease of various organs was noted with 
bullous pemphigoid group of patients. 
4. Linear pattern deposition of C3 at BMZ was seen in 17 patients and 
granular pattern in one patient. 
5. Colloid bodies were also seen in one BP patient, they are not specific 
for any disease. 
6. Deposition of IgM and fibrinogen, apart from other immunoreactants 
were seen in bullous pemphigoid patient. 
7. Linear IgA patient showed linear IgA deposition at BMZ. 
8. In CBDC patient IgA, IgG, IgM, C3 and fibrinogen deposition was 
seen. 
9. Multiple immunoreactant deposition was seen in bullous SLE 
patient. 
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10. In bullous SLE, immunoreactant deposition was seen in both 
granular and linear patterns. 
11. Lichen planus pemphigoides patient showed IgG and C3 deposition 
at BMZ and few colloid bodies stained with IgM and IgA. 
12. Bullous lichen planus patient showed colloid bodies stained by IgM, 
IgG, IgA and C3. Strong ragged fibrinogen band was seen at BMZ. 
13. Pemphigoid vegetans patient showed C3, IgG, IgA and fibrinogen 
deposition at BMZ. 
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PROFORMA 
Name :   Age :   Sex : 
Address :   Occupation : 
Chief Complaints :  
A) Skin blisters 
B) Oral lesions 
History of presenting illness : 
History of urticarial weals and generalized pruritus 
History of drug intake prior to the onset of lesions  
Precipitating or aggravating factors  
History of abdominal pain, diarrhoea and constipation  
History of fever, joint pain and photosensitivity  
History of blistering on trivial trauma.  
Loss of weight, loss of appetite, malena and hemetemesis  
Treatment history 
Personal history 
Family history 
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General examination : 
Pallor/icterus/cyanosis/clubbing/lymphadenopathy/edema 
Vital signs: BP: 
 PR 
 RR: 
Systemic examination 
RS 
CVS 
P/A 
CNS 
Dermatological examination : 
Vesicle/ bulla 
Distribution of vesicles/bullae, number, size, shape, content of bulla:   
haemorrhagic or clear fluid 
Presence of bulla on erythematous or non erythematous skin 
Oral or other mucous membrane involvement  
Palms and soles involvement 
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Erosions and crusting 
Hair and nail involvement 
Nikolsky and Asboe Hansen sign 
Investigations 
Hemogram 
LFT 
RFT 
Urine albumin/ sugar 
Blood sugar 
Tzanck smear 
Skin biopsy 
Direct immunofluorescence 
Diagnosis  
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